Combination of vaccination and inhibition of the PD-1 pathway

Patent metadata

Field	Value
Publication number	US-12447209-B2
Application number	US-202217822054-A
Country	US
Kind code	B2
Filing date	Aug 24, 2022
Priority date	Feb 22, 2013
Publication date	Oct 21, 2025
Grant date	Oct 21, 2025

Abstract

The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.

First claim

The invention claimed is:

1. A method of treating a subject having a cancer comprising administering to the subject:
(i) an immunogenic composition comprising mRNA encoding at least one epitope of a tumour-specific antigen (TSA), wherein said mRNA comprises a 5′ Cap and a Poly-A sequence of 25 to 400 consecutive adenosine nucleotides, wherein said mRNA is provided in complex with a cationic or polycationic carrier; and
(ii) a PD-1 pathway inhibitor, said PD-1 pathway inhibitor comprising an antagonistic antibody that binds to PD-1.

2. The method of claim 1 , wherein the subject has previously been administered a PD-1 pathway inhibitor.

3. The method of claim 1 , wherein the PD-1 pathway inhibitor is administered before said immunogenic composition.

4. The method of claim 1 , wherein the immunogenic composition and the PD-1 pathway inhibitor are administered sequentially.

5. The method of claim 1 , wherein the immunogenic composition and the PD-1 pathway inhibitor are administered concurrently.

6. The method of claim 1 , wherein the subject has a melanoma.

7. The method of claim 1 , wherein the subject has a metastatic solid tumor.

8. The method of claim 1 , wherein the PD-1 pathway inhibitor is administered intravenously.

9. The method of claim 8 , wherein the immunogenic composition is administered subcutaneously, intravenously, intradermally or intramuscularly.

10. The method of claim 9 , wherein the immunogenic composition is administered intramuscularly.

11. The method of claim 8 , wherein at least one epitope of the TSA comprises a tumour specific mutation.

12. The method of claim 8 , wherein the immunogenic composition comprises mRNA encoding at least two epitopes of the TSA.

13. The method of claim 8 , wherein the immunogenic composition comprises mRNA encoding at least two epitopes from different TSAs.

14. The method of claim 13 , wherein at least two epitopes of the different TSAs comprise tumour specific mutations.

15. The method of claim 13 , wherein at least two epitopes of the different TSAs are encoded on the same mRNA molecule.

16. The method of claim 13 , wherein the immunogenic composition comprises mRNA encoding at least three, four, five or more epitopes from different TSAs.

17. The method of claim 16 , wherein the epitopes of the different TSAs are encoded on the same mRNA molecule.

18. The method of claim 16 , wherein the immunogenic composition is administered intramuscularly.

19. The method of claim 18 , wherein the mRNA comprises a modification of a nucleobase.

20. The method of claim 18 , wherein the carrier comprises a cationic or polycationic lipid.

21. The method of claim 1 , wherein the antagonistic antibody that binds to PD-1 is a bispecific antibody.

22. The method of claim 1 , wherein the antagonistic antibody that binds to PD-1 is MDX-1106, CT-011 or MK-3475.

23. The method of claim 22 , wherein the antagonistic antibody that binds to PD-1 is MDX-1106.

24. The method of claim 22 , wherein the antagonistic antibody that binds to PD-1 is CT-011.

25. The method of claim 22 , wherein the antagonistic antibody that binds to PD-1 is MK-3475.

26. The method of claim 25 , wherein the PD-1 pathway inhibitor is administered intravenously.

27. The method of claim 26 , wherein the immunogenic composition is administered subcutaneously, intravenously, intradermally or intramuscularly.

28. The method of claim 27 , wherein the immunogenic composition is administered intramuscularly.

29. The method of claim 28 , wherein at least one epitope of the TSA comprises a tumour specific mutation.

30. The method of claim 29 , wherein the carrier comprises a cationic or polycationic lipid.

31. The method of claim 29 , wherein the subject has a melanoma.

32. The method of claim 29 , wherein the subject has a metastatic solid tumor.

33. The method of claim 29 , wherein the subject has non-small lung cancer (NSCLC).

34. The method of claim 29 , wherein the subject has a renal carcinoma.

35. The method of claim 29 , wherein the subject has a bladder cancer.

Assignees

• CureVac SE
• Cure Vac SE

Inventors

• Fotin-Mleczek Mariola
• Kallen Karl-Josef
• Probst Jochen

Classifications

• A61K39/0011

  Cancer antigens · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• C07K16/2803

  against the immunoglobulin superfamily · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title